A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Clinical trial NCT07475026 · RECRUITING
Trial details
- NCT number
- NCT07475026
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-09
- Primary completion
- 2030-01-31
- Enrollment
- 198
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.